Entrada Therapeutics, Inc.
TRDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $240,483 | $277,798 | $371,309 | $706,173 |
| - Cash | $93,286 | $72,482 | $67,837 | $101,211 |
| + Debt | $52,400 | $54,743 | $56,997 | $59,207 |
| Enterprise Value | $199,597 | $260,059 | $360,469 | $664,169 |
| Revenue | $1,614 | $1,950 | $20,558 | $37,398 |
| % Growth | -17.2% | -90.5% | -45% | – |
| Gross Profit | -$36,747 | $1,950 | $20,558 | $37,398 |
| % Margin | -2,276.8% | 100% | 100% | 100% |
| EBITDA | -$42,250 | -$45,815 | -$20,844 | -$4,875 |
| % Margin | -2,617.7% | -2,349.5% | -101.4% | -13% |
| Net Income | -$44,134 | -$43,103 | -$17,349 | $1,131 |
| % Margin | -2,734.4% | -2,210.4% | -84.4% | 3% |
| EPS Diluted | -1.06 | -1.04 | -0.42 | 0.026 |
| % Growth | -1.9% | -147.6% | -1,697% | – |
| Operating Cash Flow | -$28,313 | -$29,489 | -$38,507 | -$31,605 |
| Capital Expenditures | $171 | -$275 | -$1,144 | -$635 |
| Free Cash Flow | -$28,142 | -$29,764 | -$39,651 | -$32,240 |